Results 221 to 230 of about 21,169 (256)

Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer

Journal of Cellular Biochemistry, 2003
AbstractProstate specific membrane antigen (PSMA), is a unique membrane bound glycoprotein, which is overexpressed manifold on prostate cancer as well as neovasculature of most of the solid tumors, but not in the vasculature of the normal tissues. This unique expression of PSMA makes it an important marker as well as a large extracellular target of ...
CARDILLO, MARIA ROSARIA, GENTILE, Vincenzo, DI SILVERIO, Franco   +2 more
openaire   +2 more sources

Induction of Antibodies against Prostate-Specific Membrane Antigen (PSMA) by Vaccination with a PSMA DNA Vector

European Urology, 2002
Prostate-specific membrane antigen (PSMA) is a 750 amino acid surface protein expressed primarily in prostate epithelium, and is upregulated 10-fold in prostate cancer. It is therefore an attractive target for immunotherapy. However, most reported antibodies to PSMA apparently recognize epitopes in the residue 43-570 region of the extracellular domain,
Katsuyuki, Kuratsukuri, Ching Y, Wang, Tomomichi, Sone, Nobuyasu, Nishisaka, Richard F, Jones, Gabriel P, Haas   +5 more
openaire   +2 more sources

Predictors of Prostate-specific Membrane Antigen (PSMA/FOLH1) Expression in a Genomic Database

Urology, 2020
To assess predictors of prostate-specific membrane antigen (PSMA) expression in a genomic database; positron emission tomography with PSMA-targeted radiopharmaceuticals is increasingly being utilized.The de-identified Decipher Biosciences database, which includes expression for more than 46,000 coding and noncoding genes per patient, was queried for ...
Clinton D, Bahler, Melissa M, Johnson, Elai, Davicioni, Jingbin, Zhang, Liang, Cheng, Mark A, Green, Michael O, Koch   +6 more
openaire   +2 more sources

Prostate-specific membrane antigen (PSMA)-mediated laminin proteolysis generates a pro-angiogenic peptide

Angiogenesis, 2016
Prostate-specific membrane antigen (PSMA) is a membrane-bound glutamate carboxypeptidase expressed in a number of tissues. PSMA participates in various biological functions depending on the substrate available in the particular tissue; in the brain, PSMA cleaves the abundant neuropeptide N-acetyl-aspartyl-glutamate to regulate release of key ...
Rebecca E, Conway, Camilo, Rojas, Jesse, Alt, Zora, Nováková, Spencer M, Richardson, Tori C, Rodrick, Julio L, Fuentes, Noah H, Richardson, Jonathan, Attalla, Samantha, Stewart, Beshoy, Fahmy, Cyril, Barinka, Mallika, Ghosh, Linda H, Shapiro, Barbara S, Slusher   +14 more
openaire   +2 more sources

Preparation and evaluation of carborane-derived inhibitors of prostate specific membrane antigen (PSMA)

Dalton Trans., 2014
Carborane-derived inhibitors of prostate specific membrane antigen are reported. Compounds were prepared from C-hydroxy-carboranes and screened in vitro and in vivo.
Mohamed E, El-Zaria, Afaf R, Genady, Nancy, Janzen, Christina I, Petlura, Denis R, Beckford Vera, John F, Valliant   +5 more
openaire   +2 more sources

Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells

The Prostate, 2000
Prostate-specific membrane antigen (PSMA) is a glutamate carboxypeptidase that cleaves terminal carboxy glutamates from both the neuronal dipeptide N-acetylaspartylglutamate (NAAG) and gamma-linked folate polyglutamate. The prostate enzyme has activity in both the membrane and cytosolic fractions termed PSMA and PSMA', respectively.Using a NAAG ...
R G, Lapidus, C W, Tiffany, J T, Isaacs, B S, Slusher   +3 more
openaire   +2 more sources

V07-10 PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA)-TARGETED PROSTATE BIOPSY

Journal of Urology, 2023
David Kuppermann, Jeremie Calais, Leonard Marks   +2 more
openaire   +1 more source

Biochemical and Molecular Characterization of the Prostate-Specific Membrane Antigen (PSMA)

1995
Prostate cancer is the most common malignancy and the second leading cause of cancer death in males in the United States. Additionally, the number of deaths attributed to prostate cancer is increasing at a rate of approximately 8% a year. Development of new diagnostic and therapy strategies are needed in order to improve the life expectancy of patients
openaire   +1 more source

Integrative oncology: Addressing the global challenges of cancer prevention and treatment

Ca-A Cancer Journal for Clinicians, 2022
Jun J Mao,, Msce, Lorenzo Cohen, Karen M Mustian   +2 more
exaly  

Albumin-based nanoformulation for prostate-specific membrane antigen (PSMA)

Nuclear Medicine and Biology, 2014
Sangeeta R. Banerjee, Baiqi Wang, Mrudula Pullambhatla, Catherine A. Foss, Martin G. Pomper, Russell H. Morgan   +5 more
openaire   +1 more source